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Abstract
Background: Approximately 800,000 children die each year due to pneumococcal disease and .90% of these deaths occur
in developing countries where few children have access to life-saving serotype-based vaccines. Understanding the serotype
epidemiology of invasive pneumococcal disease (IPD) among children is necessary for vaccine development and
introduction policies. The aim of this study was to systematically estimate the global and regional distributions of serotypes
causing IPD in children ,5 years of age.
Methods and Findings: We systematically reviewed studies with IPD serotype data among children ,5 years of age from
the published literature and unpublished data provided by researchers. Studies conducted prior to pneumococcal
conjugate vaccine (PCV) introduction, from 1980 to 2007, with $12 months of surveillance, and reporting $20 serotyped
isolates were included. Serotype-specific proportions were pooled in a random effects meta-analysis and combined with PD
incidence and mortality estimates to infer global and regional serotype-specific PD burden. Of 1,292, studies reviewed, 169
were included comprising 60,090 isolates from 70 countries. Globally and regionally, six to 11 serotypes accounted for
$70% of IPD. Seven serotypes (1, 5, 6A, 6B, 14, 19F, 23F) were the most common globally; and based on year 2000 incidence
and mortality estimates these seven serotypes accounted for .300,000 deaths in Africa and 200,000 deaths in Asia.
Serotypes included in both the 10- and 13-valent PCVs accounted for 10 million cases and 600,000 deaths worldwide.
Conclusions: A limited number of serotypes cause most IPD worldwide. The serotypes included in existing PCV formulations
account for 49%–88% of deaths in Africa and Asia where PD morbidity and mortality are the highest, but few children have
access to these life-saving vaccines.
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Pneumonia, sepsis, and meningitis together comprise .25% of
the 10 million deaths that occur in children ,5 y of age worldwide
[1]. Streptococcus pneumoniae (SP, pneumococcus) is the leading
bacterial cause of these diseases. The World Health Organization
(WHO) estimates that approximately 800,000 children die each
year of pneumococcal disease (PD), and 90% of these deaths occur
in developing countries [2].
Three pneumococcal conjugate vaccines (PCVs) are currently
available and are protective in young children. A 7-valent vaccine
(PCV7, Prevnar, Pfizer) was licensed in 2000 and contains SP
serotypes 4, 6B, 9V, 14, 18C, 19F, 23F—the serotypes most
commonly causing invasive PD (IPD) among young children in
North America (NA). PCV10 (Synflorix, GlaxoSmithKline) was
licensed for use in Canada, Australia, and Europe in late 2008 to
early 2009 and contains PCV7serotypes plus serotypes 1, 5,and 7F.
PCV13 (Prevnar13, Pfizer) added serotypes 3, 6A, and 19A to the
PCV10 serotypes and was licensed in Chile and by the European
Medicines Agency in 2009. PCV7 is currently being replaced by
PCV13 vaccine as manufacturing and supply are scaled up. Both
PCV10 and PCV13 are eligible for the Pneumococcal Advance
Market Commitment (AMC) and both manufacturers have agreed
to supply Global Alliance for Vaccines and Immunisation (GAVI)
Alliance–eligible countries as part of the AMC.
Despite the availability of PCV7 since 2000, few countries in
geographic regions with the highest burden of pneumococcal
disease have introduced the vaccine into national immunization
programs. In October 2006, WHO convened an expert
consultation meeting to evaluate the minimum or optimal serotype
composition of PCVs for use in resource-poor countries. Estimates
of serogroup distributions were published in year 2000 by
Hausdorff et al., but since then, additional data have become
available on serotypes for countries in regions where disease
burden is the highest [3]. After reviewing IPD epidemiology and
existing literature on the global distribution of serotypes [3], the
expert group concluded that updated estimates of serotype
distribution were needed [4].
In February 2007, the GAVI Alliance announced a US$1.5
billion Pneumococcal AMC, to fund a novel vaccine-financing
mechanism to accelerate the development and introduction of
pneumococcal vaccines for the world’s poorest countries (GAVI
Alliance–eligible: countries with a gross national income per capita
,US$1,000 in year 2003). Essential to the Pneumococcal AMC
was the establishment of minimum vaccine product specifications,
also known as the target product profile (TPP), for a vaccine to be
eligible for AMC funds. Here we report the systematic review and
meta-analysis of serotypes causing IPD in children ,5 y as part of
the Pneumococcal Global Serotype Project (GSP), which estimat-
ed global and regional serotype distribution, serotype-specific
disease burden, and the potential public health impact of PCV
formulations to inform decision making regarding pneumococcal
vaccine development and introduction.
Methods
We performed a systematic review of the published literature
and meta-analysis using a protocol developed by the authors and
summarized below.
Human Research
This research was not considered human participants research
and therefore did not require approval by an Institutional Review
Board.
Sources of Data
We identified articles published as of July 15, 2007 with serotype
data pre-PCV introduction from IPD cases (defined as isolation of
SP from a normally sterile site) among children ,5y b y
systematically searching 12 literature databases (PubMed, Med-
line, Embase, Global Health Database, Biosis, PASCAL, Current
Contents, African Index Medicus, Index Medicus for the WHO
Eastern Mediterranean Region [IMEMR], Latin American and
Caribbean Health Sciences Information (LILACS), Health
Literature, Library and Information Services (HELLIS), which
also contains Index Medicus for the South East Asia Region
[IMSEAR]), modifying established keywords and search terms
described elsewhere (Table S1) [5]. The reference lists of retrieved
papers were searched for further studies. We also contacted
researchers known to carry out IPD surveillance and requested
supplemental and unpublished serotype data, some of which
became available in the public domain after July 15, 2007. Non-
English language articles were included and extracted by
abstractors proficient in the relevant languages.
Inclusion Criteria
We included studies reporting at least 20 serotyped pneumo-
coccal isolates obtained from normally sterile sites (e.g., blood,
cerebrospinal fluid, pleural fluid) conducted since year 1980 with a
duration of at least 12 mo of surveillance due to the seasonal
nature of PD and, for the US, Canada, Australia, and Europe, pre-
PCV7 national introduction. Where possible, data were limited to
children ,5 y of age, excluding neonates. However, data were
frequently presented in aggregate with older children and we
attempted to contact every author to obtain serotype data limited
to children ,5 y of age. In consultation with our External Expert
Committee (EEC), who provided technical review and advice on
our study methods and interpretation of analyses, we decided to
include studies with serotype data from children age $60 mo if
data were presented in aggregate with serotype data from children
age 0–59 mo in order to improve geographic representativeness of
the serotype data included in the analysis, particularly in high
disease-burden regions. We assumed most cases in these studies
occurred among children #5 y of age and included studies in NA
and Europe through 83 mo of age consistent with epidemiology of
pneumococcal disease. For all other countries and regions where
data were less plentiful, we included studies with aggregated
serotype data through 215 mo of age. Additional serotype data
from children were available from countries but not included in
the analysis if the serotype data were presented in aggregate with
children older than these respective age cutoffs (i.e., 83 mo of age
in NA and Europe and 215 mo of age in all other geographic
regions). Studies testing or reporting only serotypes included in
existing vaccine formulations (e.g., only reported PCV7 vaccine
serotype coverage) were excluded from the analysis because of the
potential bias of underreporting nonvaccine serotypes.
Data Collection and Management
Two reviewers abstracted each study using a pretested paper
form. Data abstracted included study design and setting, and the
proportion of IPD caused by each serotype stratified by age,
syndrome (i.e., meningitis, pneumonia, nonpneumonia/nonme-
ningitis, e.g., bacteremia without a focus, and IPD not otherwise
specified), specimen type, and HIV status. Definition of syndrome
was based on author report and no attempt was made to
standardize definitions across studies. Discrepant data were
reabstracted by a third reviewer whose abstraction was considered
final. Data were double-entered into a customized Microsoft
Access database (Microsoft), which included several data checks to
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Data Analysis
The proportion of IPD due to each serotype was estimated
independent of the other serotypes using marginal random-effects
meta-analysis within geographic regions defined according to
United Nations definitions to estimate regional serotype distribu-
tions [6,7]. Serogrouped isolates that were not further subtyped
were apportioned into serotypes by applying the regional serotype
estimates for that serogroup from the current analysis. A small
nonzero value (0.5 isolates to the numerator and denominator) was
added to all observations to accommodate serotypes reported as
0% whose study weights (the inverse of the variance) would
otherwise be undefined. To minimize the resulting bias intro-
duced, estimation was limited to only 21 serotypes and an
aggregate ‘‘all other serotypes’’ category. The selection of
serotypes to be modeled was based on the top 20 most common
serotypes globally after adjusting for regional PD incidence in a
preliminary analysis restricted to studies with all isolates serotyped
(Table S2). The serotypes identified as the top 20 globally included
the PCV13 serotypes and the 13 most common serotypes in each
region with the exception of serotype 9A. Serotype 9A was among
the top 13 ranked serotypes in NA but not among the 20 most
common global serotypes (ranked 25th), thus it was added as the
21st serotype to be estimated. To normalize serotype estimates so
they sum to 100%, each independently estimated serotype
proportion was divided by the sum of the proportions. The
uncertainty range for each serotype proportion was estimated by
the 95% confidence interval (CI) from the meta-analysis and lower
bounds were set to zero if negative. The same statistical methods
were applied to provide estimates using other categories for
stratified analysis including serotype distribution by region
excluding the single country with the greatest number of isolates
in the regional analysis, by GAVI Alliance eligibility, and
distribution of serotypes by age group.
Concordance of the serotype proportions observed among
individual studies used within a regional analysis was examined by
calculating the intraclass correlation (ICC) for each serotype [8].
When the ICC is high (i.e., informally defined as between 0.7 and
1.0), the variability in serotype proportion between studies is
considered small compared to the natural statistical variation
within a study (i.e., within-study variance). By contrast, when the
ICC is low (i.e., ,0.5), different studies are as, or more, variable in
their reporting of a given serotype proportion than the natural
statistical variation within a study.
To estimate the global serotype distribution, regional serotype
distributions were weighted by WHO global burden of disease
estimates of regional incidence of PD cases (GBD Project) [2].
Serotype-specific PD incidence and mortality were estimated by
multiplying the regional serotype distributions by the GBD Project
incidence and mortality estimates [2]. Identical serotype distribu-
tion for both bacteremic and nonbacteremic PD was assumed for
both cases and deaths. To estimate the uncertainty, we multiplied
the upper and lower bounds of the 95% CI for each serotype
proportion by the upper and lower uncertainty bounds from the
GBD Project estimates [2].
PCV7, PCV10, and PCV13 serotype coverage was defined as
the sum of the vaccine-type serotype proportion meta-analysis
estimates with 95% CIs estimated using bootstrapping methodol-
ogy [9]. We assumed serotype 6A/6B cross-protection for PCV7
and PCV10 on the basis of evidence from PCV efficacy trials and
postvaccine introduction impact data from the US Centers for
Disease Control and Prevention Active Bacterial Core surveillance
[10–12]. To estimate the burden of disease associated with specific
PCV formulations, the vaccine serotype coverage for IPD was
multiplied by the GBD Project incidence and mortality estimates
for PD [2].
Statistical analyses were conducted in SAS (Version 9.1.3, SAS
Institute) and validated by a second statistical programmer. An
EEC and ad hoc consultations with other relevant experts provided
technical review and advice on the study methods and interpre-
tation of analyses.
Results
Data Reviewed
We identified 1,232 published articles and reports and
researchers provided unpublished data from an additional 60
studies (Figure S1; Text S1). We retrieved the full text of 618
articles after title and abstract screening and removal of duplicate
data (n=44). Full-text screening excluded studies without SP
isolated from a sterile site (n=139), or serotype data (n=161), or if
reported serotype data were not abstractable for study purposes
(e.g., presented in aggregate with age group/specimens not
meeting inclusion criteria) (n=149).
169 studies were included in the final analysis, representing 70
countries and 60,090 serotyped isolates (Table 1). Every
geographic region contributed a substantial number of studies
(range: 16–42) and isolates (range: 3,649–18,788), with the fewest
number of isolates from Oceania (3,649) and Asia (4,752). The
number of isolates from studies included in the analysis range from
20 to 8,221, and most studies in Africa, Asia, and Europe reported
serotype data for less than 100 IPD cases. Studies typically report a
smaller number of serotyped isolates if the surveillance (a) has less
sensitive detection methods, (b) is of shorter duration, or (c) does
not serotype isolates from all identified cases. Half of the serotype
data in the analysis (from 42/169 studies) was either unpublished
or supplemental to published data obtained from contacted
authors (Table S3) and review of these data enabled abstraction
of serotype data for all serotypes tested for, in contrast to published
data in which serotype data for less common serotypes were
frequently not reported.
Regional Serotype Distribution
Regional estimates of the proportion of IPD among young
children showed that a limited number of serotypes seem to cause
most IPD worldwide (Figure S2). The number of serotypes
accounting for $70% of IPD ranged from 6 in NA (95% CI 5–7)
to 9 in Africa (95% CI 8–11) and 11 in Asia (95% CI 9–13) (Figure
S3). Seven serotypes (1, 5, 6A, 6B, 14, 19F, and 23F) were the most
common globally (Figure 1), the seven most common in both
Africa and Asia, and accounted for 58%–66% of IPD in every
region (Figure S2). Each region had a single country with a
significantly greater number of isolates than any other country in
that region (i.e., Asia, Israel; Africa, South Africa; Latin America
and Caribbean (LAC), Brazil; NA, US; Europe, United Kingdom:
and Oceania, Australia) (Figure S4). Excluding isolates from the
single country with the greatest number of isolates in the regional
analysis does not substantively change distributions of the African
and Asian serotypes (Figure S5).
Serotype 14 was the most common serotype accounting for
12%–29% of IPD in each region. Serotype 6B ranked second in
every region, except Africa (ranked fifth); when combined with
serotype 6A, this serogroup accounted for 14%–18% of IPD
across regions. Serotype 6C, which was identified in 2007 [13,14],
was not reported in the studies included in this analysis. Serotype
1, a known cause of meningitis outbreaks in the African meningitis
Pneumococcal Global Serotype Project
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with the highest IPD burden (Africa, Asia, and LAC). Serotype 5
ranked third in Africa and LAC, and fifth in Asia. Serotypes 1, 5,
and 14 together accounted for 28%–43% of IPD across regions.
Serotypes 23F and 19F were responsible for 9%–18% of IPD
overall. Serotype 18C was common (ranked fourth or fifth) in
regions with a large proportion of high income countries (i.e.,
Europe, NA, and Oceania). Serotype 19A, which is frequently
associated with antibiotic resistance [16], was relatively more
important in Europe (6%) than other regions (range: 3%–4%).
The heterogeneity in reported serotype prevalence varied by
serotype and region (Table S4). The top-ranked serotypes in
regions with the highest burden of pneumococcal disease (Africa,
Asia, and LAC) have low ICCs indicating high variability across
studies in the reported proportion of IPD due to these serotypes. In
geographic regions with low ICCs for the reported serotypes, the
addition or removal of studies has a large impact on the overall
regional meta-estimate for those serotypes. In Africa, ten serotypes
had an ICC,0.2, thus the meta-estimates for these ten serotypes
are particularly sensitive to the addition or removal of serotype
data in this region. Asia and LAC also had a large number of
serotypes with ICC,0.2 (six and five serotypes, respectively). By
contrast, in Oceania, only serotype 14 had an ICC,0.2,
indicating relative homogeneity in the reported serotype propor-
tion data for this region. Higher ICC values for less common
serotypes may reflect the bias in underreporting of less common
serotypes in published studies, or may be due, in part, to the
methods used in this analysis, including inclusion of studies with a
small number of serotyped isolates that are unable to estimate the
proportion of IPD caused by less prevalent serotypes; and, further,
the addition of a small nonzero value to serotype proportions to
accommodate serotypes reported as 0% whose study weights
would otherwise be undefined, which has a greater impact on the
estimated proportion of IPD due to less common serotypes.
Serotype Distribution by GAVI Alliance Eligibility
Serotype data (4,678 isolates) available from 20 of the world’s 72
poorest countries (GAVI Alliance–eligible countries) showed that
serotypes 14, 5, and 1 were the most common serotypes accounting
for .30% of IPD (Figure 2). In non-GAVI Alliance–eligible
countries, serotype 14 caused most (24%) IPD, and serotypes 1 and
5 ranked fifth and eighth, respectively. Serotypes 6B, 19F, and 23F
were the next most commonly observed serotypes for both GAVI
Alliance- and non-GAVI Alliance–eligible countries.
Serotype Distribution by Age Group
In 49 studies with serotype data available for both ,2- and $2-
y-old age groups, approximately 26% of the 25,493 isolates were
from children $2 y of age. While serotype 14 dominated the
global serotype distribution for both age groups, serotype 1 was
less common among children ,2 y of age (ranked ninth) than
among 2–4 year olds (ranked second; Figure 3); similar findings
were observed in each region (unpublished data).
Serotype-Specific Disease Burden
Based on the year 2000 WHO GBD Project incidence and
mortality estimates, the seven global serotypes (1, 5, 6A, 6B, 14,
19F, and 23F) account for approximately 9 million cases and
500,000 deaths due to PD in children ,5 y of age. In areas of high
PD incidence (i.e., Africa, Asia, LAC, Oceania), the incidence
accounted for by the three most common serotypes exceeded the
total PD incidence and mortality rate in NA and Europe (Tables
S6, S7, S8, S9).
Table 1. Summary of serotype data available for analysis.
Serotype Data Category Africa Asia Europe LAC NA Oceania
Total
(Global)
n Countries (percent of
countries in region)
— 13/53 (24.5) 18/47 (38.3) 16/42 (38.1) 17/33 (51.5) 2/2 (100.0) 4/16 (15.0) 70/193 (36.3)
n GAVI-eligible countries
(percent of countries in region)
— 10/39 (25.6) 6/22 (27.3) 0/2 (0.0) 3/6 (50.0) 0/0 (0.0) 3/3 (100.0) 20/72 (27.8)
n Studies — 22 33 39 42 17 16 169
n Studies by n serotyped isolates in
study (percent of studies in region):
20–49 7 (31.8) 7 (21.2) 13 (33.3) 4 (9.5) 2 (11.8) 4 (25.0) 37 (21.9)
50–99 4 (18.2) 11 (33.3) 9 (23.1) 8 (19.1) 2 (11.8) 2 (12.5) 36 (21.3)
100–199 6 (27.3) 9 (27.3) 5 (12.8) 10 (23.8) 2 (11.8) 5 (31.3) 37 (21.9)
200–499 2 (9.1) 5 (15.2) 8 (20.5) 9 (21.4) 6 (35.3) 1 (6.3) 31 (18.3)
$500 3 (13.6) 1 (3.0) 4 (10.3) 11 (26.2) 5 (29.4) 4 (25.0) 28 (16.6)
n Studies with serotype data stratified
for children age ,2 y and $2y
(percent of studies in region)
11/22 (50.0) 8/33 (24.2) 12/39 (23.1) 4/42 (9.5) 11/17 (64.7) 6/16 (37.5) 49/169 (29.0)
n Studies by syndrome
(percent of studies in region):
Meningitis Only 3/22 (13.6) 3/33 (9.1) 3/39 (7.7) 5/42 (11.9) 0/17 (0.0) 0/16 (0.0) 14/169 (8.3)
Nonmeningitis only 1/22 (4.6) 3/33 (9.1) 4/39 (10.3) 1/42 (2.4) 1/17 (5.9) 1/16 (6.2) 11/169 (6.5)
Mixed
a 18/22 (81.8) 27/33 (90.8) 32/39 (82.0) 36/42 (85.7) 16/17 (94.1) 15/16 (93.8) 144/169 (85.2)
n Isolates — 11,181 4,752 10,279 18,788 11,441 3,649 60,090
n Isolates per 100,000
children ,5 y in year 2000
— 9 1 2 83 45 31 3 6 9
aStudies with cases from any of the following syndromes: meningitis, pneumonia, nonpneumonia/nonmeningitis (e.g., bacteremia without a focus), invasive disease not
specified/unknown.
doi:10.1371/journal.pmed.1000348.t001
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Serotypes included in PCV7 accounted for $49% of IPD in
each region, but this percentage varied substantially by region
(range: 49%–82%), with highest serotype coverage in NA and
Europe (Figure 4A). Coverage of PCV10 was similar to PCV13,
with serotypes accounting for $70% of IPD in every region and
less regional variability (range: 70%–84% and 74%–88%,
respectively) than with PCV7 (Figures 4, and S6, S7, S8). Globally,
PCV7 serotypes accounted for approximately 7.4 million cases
and 400,000 deaths due to PD in children ,5 y of age (Figure 4B,
4C). The additional serotypes in PCV10 and PCV13 accounted
for another 2.8 and 3.4 million PD cases and 170,000 and 200,000
PD deaths, respectively.
Discussion
Our findings contradict the conventional supposition that the
most common serotypes causing IPD vary greatly across
geographic regions. Serotype 14 was the most common cause of
IPD in every region, and seven serotypes (1, 5, 6A, 6B, 14, 19F,
23F) accounted for more than half of IPD in every region.
Serotype 1 was an important cause of IPD in Africa, Asia, and in
Europe, contravening the widely held notion that this serotype is
only common in developing country settings [4]. Although we
identified seven serotypes common across regions, the proportion
of IPD caused by these serotypes varied across and within regions.
The serotypes included in existing PCVs are responsible for a large
portion of IPD in every region; PCV10 and PCV13 provide
considerably greater coverage than PCV7 in regions with the
largest PD burden. Serotypes not included in existing vaccine
formulations are less common, therefore serotype-based vaccine
formulations developed to extend valency beyond the existing
PCV13 may only confer a marginal additional serotype coverage
and may be more complex and costly to manufacture.
Our region-specific estimates of vaccine serotype coverage are
consistent with those provided elsewhere [3,10,16]. We estimated
82% (95% CI 78%–84%) PCV7 serotype coverage (assuming
serotype 6A/6B cross-protection) for NA, which is consistent with
the observed 78% (95% CI 74%–82%) reduction in IPD vaccine
and vaccine-related serotypes post-PCV7 introduction in the US
before significant herd effects were seen [10]; and, similar to
previous estimates, PCV7 serotype coverage in NA is approxi-
mately 10% greater than for Europe [3].
There were notable differences in our results compared with
those from the year 2000 analysis by Hausdorff et al. [3], which
may be attributable to differences in the included studies,
availability of serotype versus serogroup data, and the statistical
modeling methods used (random versus fixed-effects meta-analysis
in Hausdorff et al.). The serotype analysis presented here includes
more than double the number of studies, isolates, and data from
developing countries than the analysis by Hausdorff et al. [3]. The
number of isolates that were serogrouped and not further subtyped
in the present analysis were few (6.7% of all isolates) and were
typically more common serogroups (6, 18, 19, 23) for which robust
Figure 1. Proportion of IPD in young children due to the most common serotypes globally. Error bars indicate the 95% CI for the
proportion of invasive PD due to each of the 21 serotypes. Cumulative line indicates the cumulative proportion of invasive PD due to the 21
serotypes. *Adjusted for regional incidence of cases.
doi:10.1371/journal.pmed.1000348.g001
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across serotypes.
doi:10.1371/journal.pmed.1000348.g002
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lack of available serotype data, Hausdorff et al. provided estimates
of serogroup distribution only, and therefore estimates of vaccine
serotype coverage were less specific. Hausdorff et al. found lower
PCV7 serotype coverage in Asia (,30%) compared to our study
(,50%), and that the important serotypes in Africa differed from
those in Asia [3], whereas we found that the seven most common
serotypes in Africa were identical to those in Asia, albeit the
proportion of IPD caused by those serotypes varied.
A limitation of the review by Hausdorff et al. and the present
analysis is the inclusion of isolates from children age $60 mo in
the analysis that estimates serotype distribution for young children
(see Table S10). Serotype 1 is more important in older children (as
seen in Figure 3; additional unpublished data), thus it is possible
that the estimates of proportion of IPD caused by serotype 1 are
slightly overestimated, but the effect is likely minimal due to the
lower incidence of IPD in this age group. Additional limitations
include those common in analyses of published data: (a) data are
often presented in aggregate without further specification (i.e., in
‘‘other’’); (b) data stratified by categories are inconsistent with
variables of interest thus limiting the availability of data for
stratified analyses (e.g., serotype distribution by HIV status and
syndrome); and (c) difficulty in interpreting missing serotype data
as either not tested for, or tested for and not reported, or tested for
and grouped in ‘‘other.’’ Analysis of syndrome-specific serotype
distribution is confounded by age and therefore not reported here
but multivariable analyses using large datasets with case-level data
are currently underway and expected to provide further insights
into serotype distribution differences by age, syndrome, and HIV
status.
Several features of the serotype data limited the feasibility of
more sophisticated statistical methods. We abstracted and used the
serotype proportions reported in each study in the analysis and
could also have analyzed logit transformations of the proportions,
but this would likely only impact estimates for less prevalent
serotypes for which few studies included a sufficient number of
isolates to be able to estimate the proportion of IPD caused by less
common serotypes. Compositional multivariate statistical methods
such as multinomial logistic regression were preferred but not
feasible due to the large number of serotypes (i.e., categories)
estimated, because different serotypes were reported across studies,
and, because it was difficult to interpret missing serotype data as
mentioned previously. Additionally, we used simple (single) rather
than multiple imputation to apportion serogroup data to subtypes,
which could have underestimated the variability in serotype
proportions, but since only 6.7% of all isolates included in the
analysis were not subtyped the effect should be minimal.
Owing to the lack of serotype-specific incidence and mortality
data available in the published literature, our estimates relied on
serotype prevalence among cases of IPD estimated from the
literature applied to existing pneumococcal morbidity and
mortality estimates. Estimates of serotype-specific incidence
assumed the same serotype distribution for both bacteremic and
nonbacteremic disease (i.e., IPD and PD); and serotype-specific
mortality assumed uniform risk of mortality for each serotype,
which may not be entirely correct, therefore serotype-specific
estimates of morbidity and mortality may be slightly over- or
underestimated for individual serotypes.
A strength of the present analysis is the inclusion of a large
number of studies and isolates covering more than 20 y allowing
for a ‘‘smoothing’’ of secular trends and small studies to estimate
the average serotype distribution causing PD globally and
regionally over time. Secular trends and outbreaks of serotype
distribution are known to occur [17–19]. Studies of short duration
risk over- or underestimating serotype coverage due to inability to
take into account the periodicity of serotypes.
Serotype data from a large number of countries also strengthen
the regional estimates. Although limited or no data are included
from countries with the largest populations of children ,5 y of age
(e.g., mainland China and India each contributed ,250 isolates,
and no isolates were included from Indonesia and Nigeria),
serotype data from neighboring countries (e.g., Pakistan, Bangla-
desh, Papua New Guinea, Taiwan, Hong Kong, Ghana, Burkina
Faso) are included in this analysis and ensure some representation
of data from these subregions. While additional data might allow
for generation of subregional estimates and an assessment of the
effects of age, syndrome, HIV status, or other factors on the
distribution of serotypes, it is unlikely that additional pre-PCV
introduction serotype data would significantly change the regional
inferences of this analysis (Figure S5). However, continued
surveillance is needed to monitor trends in serotype distribution
post-PCV introduction to evaluate the impact and value of specific
vaccines and immunization strategies.
The large amount of serotype data available for this analysis
reflects an increase in awareness and support for surveillance of
bacterial pneumonia and meningitis [20–24]. In addition to
estimates of vaccine serotype coverage, this is the first report, to
our knowledge, of global estimates of serotype-specific PD
incidence and mortality, allowing us to project the potential
public health impact of existing PCV formulations. With
advancements in vaccine development and financing mechanisms
for vaccine procurement, estimates of disease burden and serotype
distribution are essential to inform decision making for vaccine
introduction and to monitor vaccine impact.
PD is the leading vaccine-preventable disease among children
,5 y of age globally [25]. Until recently, countries with high PD
incidence and mortality have not had access to life-saving
pneumococcal vaccines. In April 2009, Rwanda was the first
GAVI Alliance–eligible country to introduce PCV into routine
childhood immunizations. Other countries are contemplating or
preparing policy analyses of PCV products. Although we do not
provide country-level estimates of serotype distribution, country-
specific vaccine impact estimates can be made using country-level
PD burden numbers combined with the regional serotype
estimates provided here [2]. Use of these regional serotype
prevalence estimates in vaccine impact calculations and cost-
effectiveness analyses are underway and will provide country-level
policy makers with estimates of the potential impact of various
PCV formulations, which should contribute substantially to the
decision-making process. Likewise manufacturers can work from a
consensus set of serotype coverage estimates to plan and design
future serotype-based vaccine formulations targeting the greatest
pneumococcal disease burden. Recent progress towards increasing
access to PCVs in high-burden countries will contribute to
achieving the year 2015 Millennium Development Goal 4 target
to reduce child mortality by two-thirds [26].
Figure 3. Proportion of IPD in young children globally due to the most common serotypes by age. (A) children age 0–23 mo (n=18,829
isolates) and (B) children age 24–59 mo (n=6,664 isolates). Error bars indicate the 95% CIs. Line indicates the cumulative proportion of IPD across
serotypes. *Limited to studies (n=49) with serotype data available for both age groups.
doi:10.1371/journal.pmed.1000348.g003
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PLoS Medicine | www.plosmedicine.org 8 October 2010 | Volume 7 | Issue 10 | e1000348Figure 4. (A) Proportion of IPD, number of (B) PD cases, and (C) deaths in children ,5 y of age due to serotypes in existing PCV
formulations. Assumes serotype 6A/6B cross-protection, globally and by region. Error bars indicate the 95% CIs (A) or uncertainty estimates (B, C).
PCV7 serotypes include: 4, 6B, 9V, 14, 18C, 19F, 23F. PCV10 adds serotypes: 1, 5, and 7F. PCV13 adds serotypes: 3, 6A, and 19A.
doi:10.1371/journal.pmed.1000348.g004
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Figure S1 Flow chart of study identification. Details of
excluded studies can be found in the text. *Other sources of data
include unpublished data received from contacted researchers.
Found at: doi:10.1371/journal.pmed.1000348.s1 (0.07 MB
DOC)
Figure S2 Proportion of IPD in young children due to
the 21 most common or important serotypes by region.
(A) Africa, (B) Asia, (C) Europe, (D) LAC, (E) NA, (F) Oceania.
Error bars indicate the 95% CIs. Line indicates the cumulative
proportion across serotypes [27].
Found at: doi:10.1371/journal.pmed.1000348.s2 (0.51 MB PDF)
Figure S3 Number of serotypes required to account for
60%, 70%, and 80% of IPD in young children by region.
Error bars indicate the 95% CIs. *Upper bound of 95% CI is .21
serotypes.
Found at: doi:10.1371/journal.pmed.1000348.s3 (0.03 MB PDF)
Figure S4 Map of the number of isolates from each
country with pneumococcal serotype data included in
the analysis. Grey areas are countries without any serotyped
isolates in the analysis.
Found at: doi:10.1371/journal.pmed.1000348.s4 (0.05 MB PDF)
Figure S5 Cumulative proportion of IPD in young
children due to the 21 most common or important
serotypes in each region. Cumulative proportion of IPD
including (red line with square marker) and excluding the single
country in the region contributing the greatest number of isolates
to the analysis (blue line with circle marker) for (A) Africa and (B)
Asia.
Found at: doi:10.1371/journal.pmed.1000348.s5 (0.02 MB PDF)
Figure S6 Proportion of IPD in young children due to
the serotypes in the existing PCV7 by region. Assumes
serotype 6A/B cross-protection. PCV7 serotypes include: 4, 6B,
9V, 14, 28C, 19F, 23F. PCV10 adds serotypes: 1, 5, and 7F.
PCV13 adds serotypes: 3, 6A, and 19A.
Found at: doi:10.1371/journal.pmed.1000348.s6 (0.05 MB PDF)
Figure S7 Proportion of IPD in young children due to
the serotypes in the existing PCV10 by region. Assumes
serotype 6A/B cross-protection. PCV10 serotypes include: 4, 6B,
9V, 14, 28C, 19F, 23F, 1, 5, and 7F.
Found at: doi:10.1371/journal.pmed.1000348.s7 (0.05 MB PDF)
Figure S8 Proportion of IPD in young children due to
the serotypes in the existing PCV13 by region. PCV13
serotypes include: 4, 6B, 9V, 14, 28C, 19F, 23F, 1, 5, 7F, 3, 6A,
and 19A.
Found at: doi:10.1371/journal.pmed.1000348.s8 (0.05 MB PDF)
Table S1 Search strategy to identify potentially relevant
studies in the published literature.
Found at: doi:10.1371/journal.pmed.1000348.s9 (0.04 MB
DOC)
Table S2 Steps in selection of serotypes modeled based
on a preliminary analysis restricted to studies with all
isolates serotyped. Step 1: Perform meta-analysis of serotype
prevalence for all 90 serotypes among studies reporting serotype
data (i.e., excluding studies reporting only serogroup data). Step 2:
Compare the rank and relative serotype prevalence of serotypes
globally and regionally to identify the most common serotypes (as
seen below). N, serotype not included in the 23-valent polysac-
charide pneumococcal vaccine; N America, North America;
PS-23, serotype included in the 23-valent polysaccharide pneu-
mococcal vaccine; RelProp, relative proportion; ST, serotype; Y,
included in the 23-valent polysaccharide pneumococcal vaccine.
Found at: doi:10.1371/journal.pmed.1000348.s10 (0.09 MB
DOC)
Table S3 Characteristics of studies included in the
analysis (n=169). GAVI Alliance–eligible countries are
indicated by (G). Studies reporting only serogroup data are
indicated by (X). Unpublished data indicated by PC (personal
communication) and supplemental data ({).
Found at: doi:10.1371/journal.pmed.1000348.s11 (0.34 MB
DOC)
Table S4 Comparison of the ICC for the serotype-
specific proportions of IPD among young children
reported across studies in each geographic region. Only
the 20 most common serotypes occurring globally are presented.
Higher ICC values indicate a higher degree of correlation.
Serotypes not observed in a region are indicated by ‘‘-.’’
Found at: doi:10.1371/journal.pmed.1000348.s12 (0.05 MB
DOC)
Table S5 Proportion (%) of IPD in young children due
to each serotype by region. 95% CI [27].
Found at: doi:10.1371/journal.pmed.1000348.s13 (0.07 MB
DOC)
Table S6 Regional incidence of pneumococcal disease
(per 100,000) in young children attributed to each
serotype. Pneumococcal disease incidence was estimated by
applying the proportion of pneumonia cases caused by SP derived
from efficacy estimates from vaccine trials to WHO country-
specific estimates of all-cause pneumonia cases then multiplied by
country estimates of populations younger than 5 y of age (for more
details on pneumococcal disease incidence estimates see [2]). LB,
lower bound of uncertainty estimate; UB, upper bound of
uncertainty estimate; SSI, serotype-specific incidence (per
100,000 children ,5 y of age).
Found at: doi:10.1371/journal.pmed.1000348.s14 (0.07 MB
DOC)
Table S7 Pneumococcal disease cases in young children
attributed to each serotype by region. Pneumococcal
disease cases were estimated by applying the proportion of
pneumonia cases caused by SP derived from efficacy estimates
from vaccine trials to WHO country-specific estimates of all-cause
pneumonia cases among children younger than 5 y of age (for
more details on pneumococcal disease cases estimates see [2]). LB,
lower bound of uncertainty estimate; UB, upper bound of
uncertainty estimate.
Found at: doi:10.1371/journal.pmed.1000348.s15 (0.08 MB
DOC)
Table S8 Pneumococcal disease mortality (per 100,000)
in young children due to each serotype globally, and by
region. Pneumococcal disease mortality was estimated by
applying the proportion of pneumonia cases caused by SP derived
from efficacy estimates from vaccine trials to WHO country-
specific estimates of all-cause pneumonia deaths then multiplied by
country estimates of populations younger than 5 y of age (for more
details on pneumococcal disease mortality estimates see [2]). LB,
lower bound of uncertainty estimate; UB, upper bound of
uncertainty estimate; SSM, serotype-specific mortality (per
100,000 children ,5 y of age).
Found at: doi:10.1371/journal.pmed.1000348.s16 (0.08 MB
DOC)
Pneumococcal Global Serotype Project
PLoS Medicine | www.plosmedicine.org 10 October 2010 | Volume 7 | Issue 10 | e1000348Table S9 Pneumococcal disease deaths in young chil-
dren attributed to each serotype by region. Pneumococcal
disease deaths were estimated by applying the proportion of
pneumonia caused by SP derived from efficacy estimates from
vaccine trials to WHO country-specific estimates of all-cause
pneumonia deaths among children younger than 5 y of age (for
more details on pneumococcal disease deaths estimates see [2]).
LB, lower bound of uncertainty estimate; UB, upper bound of
uncertainty estimate.
Found at: doi:10.1371/journal.pmed.1000348.s17 (0.08 MB
DOC)
Table S10 The number of studies in our analysis with
serotype data from children age $60 mo, by region.
Found at: doi:10.1371/journal.pmed.1000348.s18 (0.03 MB
DOC)
Text S1 PRISMA checklist.
Found at: doi:10.1371/journal.pmed.1000348.s19 (0.07 MB
DOC)
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Background Despite all the international attention on
Millennium Development Goal (MDG) 4—to reduce deaths in
children under 5 years by two thirds by 2015—pneumonia,
sepsis, and meningitis together comprise .25% of the 10
million deaths occurring annually in children ,5 years of
age. Streptococcus pneumoniae is a leading bacterial cause of
these diseases and the World Health Organization estimates
that approximately 800,000 children die each year of invasive
pneumococcal disease. Three pneumococcal conjugate
vaccines are currently available and protect against the
serotypes most commonly causing invasive pneumococcal
disease in young children in North America. However, few
countries with the highest burden of invasive pneumococcal
disease have introduced the vaccines into their national
immunization programs. Not only is it important to
introduce a vaccine, but also to use a vaccine covering the
appropriate serotypes prevalent in a susceptible region.
Why Was This Study Done? Over the past few years, data
on serotyping in many high burden countries has become
available. The authors conducted this study (a systematic
review and meta-analysis) to quantify the serotypes causing
invasive pneumococcal disease in children ,5 years of age in
order to estimate the global and regional serotype
distribution and serotype-specific disease burden. This
information can then be used to estimate the potential
public health impact of pneumococcal conjugate vaccine
formulations and help to inform decision making for both
pneumococcal vaccine development and the introduction of
a vaccine into a specific region.
What Did the Researchers Do and Find? Using
published studies and unpublished data provided by
researchers, the researchers systematically reviewed studies
that included data on invasive pneumococcal disease
serotype among children ,5 years of age. The researchers
then used statistical tools to pool the serotype-specific
proportions and combined this information with
pneumococcal disease incidence and mortality estimates to
calculate the global and regional burden of serotype-specific
pneumococcal disease.
The researchers reviewed 1,292 studies and included 169
suitable studies in their analysis, which included information
on 60,090 isolates from 70 countries. The researchers
produced regional estimates of the serotypes that caused
invasive pneumococcal disease among under five-year-olds
in different regions: six serotypes were identified as causing
most invasive pneumococcal disease in North America; nine
serotypes were identified in Africa; and 11 serotypes were
identified in Asia. The researchers also found that seven
serotypes (1, 5, 6A, 6B, 14, 19F, and 23F) were the most
common globally and that these seven serotypes accounted
for 58%–66% of invasive pneumococcal disease in every
region. On the basis of incidence and mortality estimates of
invasive pneumococcal disease for the year 2000 (before
pneumococcal conjugate vaccines were introduced), the
researchers found that these serotypes represented
.300,000 deaths in Africa and 200,000 deaths in Asia.
What Do These Findings Mean? This study shows that a
limited number of serotypes cause most invasive
pneumococcal disease worldwide. This finding contradicts
the conventional supposition that the most common
serotypes causing invasive pneumococcal disease vary
greatly across geographic regions. Crucially, the findings of
this study also show that the serotypes currently included in
existing pneumococcal conjugate formulations account for
49%–74% of deaths in Africa and Asia where the morbidity
and mortality of pneumococcal disease are the highest and
where most children do not have access to current
pneumococcal conjugate vaccines. Although the authors
do not provide country-level estimates of serotype
distribution, country-specific vaccine impact estimates can
be made using country-level pneumococcal disease burden
numbers combined with the regional serotype estimates
provided in this study. This means that national policy
makers can assess the potential impact of serotypes included
in different conjugate vaccines, which should contribute to
their decision-making process. In addition, manufacturers
can now work from a consensus set of serotype coverage
estimates to plan and design future serotype-based vaccine
formulations to target the pneumococcal disease burden.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000348
N The World Health Organization provides information about
pneumococcus
N The PneumoACTION provides information about pneumo-
nia and pneumococcal disease
N The Global Alliance for Vaccination and Immunisation has
information on all aspects of vaccination and immunization
N The US Centers for Disease Control provides information
about pneumococcal conjugate vaccination
N The Word Pneumonia Day coalition provides information
about pneumonia
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